Secretion of the C3 component of complement by peritoneal cells cultured with encapsulated Cryptococcus neoformans.
Two isolates of Cryptococcus neoformans were identified as being widely divergent in pathogenic potential after intratracheal infection of mice. These isolates differed in their ability to upregulate capsule synthesis when grown under tissue culture conditions, and this property correlated with virulence. We postulated that differential capsule synthesis may cause differential stimulation of macrophages to produce products such as complement components. To test this hypothesis, heat-killed yeast cells were incubated with normal mouse peritoneal cells (PC) before the level of C3 secreted was determined. Cryptococcal stimulants were grown on mycological agar, which does not promote capsule synthesis, or in RPMI 1640 at 37 degrees C in an atmosphere of 5% CO2, which stimulates capsule synthesis, to determine the role that the capsule plays in the induction of C3 secretion. C3 levels were elevated in cultures containing cryptococci grown in RPMI 1640 at 37 degrees C in an atmosphere of 5% CO2, and the level of C3 detected was correlated with the amount of capsule expressed by the yeast cell stimulant. Nonencapsulated mutants of C. neoformans did not stimulate C3 secretion. Purified capsular polysaccharide (glucuronoxylomannan [GXM]) also stimulated the PC to secrete C3. Two signals were required before GXM stimulated C3 secretion. The second signal was identified as endotoxin present in small amounts (0.06 ng per ml) in tissue medium. Endotoxin may provide a priming stimulus for PC to express receptors or other cytokines needed for effective stimulation of C3. These experiments show that enhancement of C3 secretion by C. neoformans is due to GXM and is correlated with the virulence of the cryptococcal isolate.
Blackstock
R
R
Department of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City 73190, USA. becky-blackstock@uokhsc.edu
Murphy
J W
JW
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D002478:Cells, Cultured; D003176:Complement C3 / Q000378:metabolism*; D003453:Cryptococcosis / Q000276:immunology / Q000401:mortality; D003455:Cryptococcus neoformans / Q000166:cytology / Q000276:immunology* / Q000472:pathogenicity; D004731:Endotoxins / Q000276:immunology; D005260:Female; D017737:Macrophages, Peritoneal / Q000166:cytology / Q000276:immunology*; D051379:Mice; D008808:Mice, Inbred CBA; D010533:Peritoneal Lavage; D011112:Polymyxin B / Q000494:pharmacology; D011134:Polysaccharides / Q000276:immunology*; D013045:Species Specificity; D014774:Virulence / Q000276:immunology
D000900:Anti-Bacterial Agents; D003176:Complement C3; D004731:Endotoxins; D011134:Polysaccharides; C027478:glucuronoxylomannan; D011112:Polymyxin B